Pharmocoepigenetics: A new approach to predicting individual drug responses and targeting new drugs

Pharmacological Reports

Volumn 63, Issue 2, 2011, Pages 293-304

  Baer Dubowska, Wanda ^a   Majchrzak Celińska, Aleksandra ^a   Cichocki, Michał ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

DNA methylation; Epigenetic drugs and chemopreventive agents; Epigenetics; Histone modification; MicroRNA; Pharmacoepigenetics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; AZACITIDINE; CELL NUCLEUS RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 3A; DAUNORUBICIN; DNA METHYLTRANSFERASE 1; DRUG METABOLIZING ENZYME; EPIGALLOCATECHIN GALLATE; ESTROGEN; ETOPOSIDE; GEMCITABINE; GLUCOCORTICOID; INTERFERON; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; PROCAINAMIDE; PROCAINE; TRICHOSTATIN A; ZEBULARINE;

3' UNTRANSLATED REGION; ADENOSINE DIPHOSPHATE RIBOSYLATION; CANCER CELL; DNA MODIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GENETIC POLYMORPHISM; HISTONE MODIFICATION; HUMAN; ISOMERIZATION; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SEQUENCE ANALYSIS; SUMOYLATION; UBIQUITINATION;

EID: 79955943143     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70498-4     Document Type: Review

References (89)

1. Abdulla P, Coe IR: Characterization and functional analysis of the promoter for the human equilibrative nucleoside transport gene, hENT1. Nucleosides Nucleotides Nucleic Acids, 2007, 26, 99-110. (Pubitemid 44949931)
2. Adams BD, Furneaux H, White BA: The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol, 2007, 21, 1132-1147.
3. Alt SR, Turner JD, Klok MD, Meijer OC, Lakke EA, Derijk RH, Muller CP: Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed. Psychoneuroendocrinology, 2010, 35, 544-556.
4. Anttila S, Hakkola J, Tuominen P, Elovaara E, Husgafvel-Pursiainen K, Karjalainen A, Hirvonen A, Nurminen T: Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. Cancer Res, 2003, 63, 8623-8628. (Pubitemid 38064036)
5. Baker EK, Johnstone RW, Zaicberg JR, El-Osta A: Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene, 2005, 24, 8061-8075. (Pubitemid 41746749)
6. Beumer JH, Tawbi H: Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol, 2010, 5, 196-208.
7. Bovenzi V, Momparler RL: Antineoplastic action of 5-aza-2′ deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol, 2001, 48, 71-76. (Pubitemid 32662439)
8. Burgers WA, Fuks F, Kouzarides T: DNA methyltransferases get connected to chromatin. Trends Genet, 2002, 18, 275-277. (Pubitemid 34607108)
9. Candelaria M, de la Cruz-Hernández E, Pérez-Cárdenas E, Trejo-Becerril C, Gutiérrez- Hernández, Dueñas- González: Pharmacogenetics and pharmacoepigenetics of gemcitabine. Med Oncol, 2010, 27, 1133-1143.
10. Christman JK: 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene, 2002, 21, 5483-5495.
11. Chuang JC, Yoo CB, Kwan JM, Li TWH, Liang G, Yang AS, Jones PA: Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther, 2005, 4, 1515-1520. (Pubitemid 41556433)
12. Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE: The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res, 2002, 112, 27-47.
13. Crick F: Central dogma of molecular biology. Nature, 1970, 227, 561-563.
14. Dannenberg LO, Edenberg HJ: Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics, 2006, 7, 181.
15. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X, Nelson WG: MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-aza-cytidine. Cancer Biol Ther, 2004, 3, 540-548. (Pubitemid 41351125)
16. Fabbri M, Calin GA: Epigenetics and miRNAs in human cancer. Adv Genet, 2010, 70, 87-99.
17. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res, 2003, 63, 7563-7570. (Pubitemid 37466673)
18. Feinberg AP: Epigenetics at the epicenter of modern medicine. JAMA, 2008, 299, 1345-1350.
19. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res, 1995, 55, 2279-2283.
20. Gal-Yam EN, Saito Y, Egger G, Jones PA: Cancer epigenetics: modifications, screening, and therapy. Ann Rev Med, 2008, 59, 267-280. (Pubitemid 351287937)
21. Ghotbi R, Gomez A, Milani L, Tybring G, Syvänen AC, Bertilsson L, Ingelman-Sundberg M, Aklillu E: Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacoepigenomics, 2009, 9, 208-217.
22. Glubb DM, Innocenti F: Mechanisms of genetic regulation in gene expression: examples from drug metabolising enzymes and transporters. Wiley Interdiscip Rev Syst Biol Med, 2011, 3, 299-313.
23. Gomez A, Ingelman-Sundberg M: Pharmacoepigenetics: Its role in interindividual differences in drug response. Clin Pharmacol Ther, 2009, 85, 426-430.
24. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sunberg M: Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics, 2007, 8, 1315-1325. (Pubitemid 350162848)
25. Grosshans H, Filipowicz W: Molecular biology: the expanding world of small RNAs. Nature, 2008, 451, 414-416. (Pubitemid 351158877)
26. WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA, 2004, 101, 1241-1246.
27. Habano W, Gamo T, Sugai T, Otsuka K, Wakabayashi G, Ozawa S: CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. Int J Oncol, 2009, 34, 1085-1091.
28. Hammons GJ, Yan-Sanders Y, Jin B, Blann E, Kadlubar FF, Lyn-Cook BD: Specific site methylation in the 5′-flanking region of CYP1A2 interindividual differences in human livers. Life Sci, 2001, 69, 839-845. (Pubitemid 32619196)
29. Hauser AT, Jung M: Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med, 2008, 74, 1593-1601.
30. Huang Y: Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev, 2007, 26, 183-201.
31. Imamura T: Epigenetic setting for long-term expression of estrogen receptor alpha and androgen receptor in cells. Horm Behav, 2011, 59, 345-352.
32. Ingelman-Sundberg M, Gomez A: The past, present and future and pharmacoepigenomics. Pharmacogenomics, 2010, 11, 625-627.
33. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphism on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther, 2007, 116, 496-526. (Pubitemid 350116943)
34. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E et al.: MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 2005, 65, 7065-7070. (Pubitemid 41161233)
35. Jackson RJ, Standart N: How do-microRNAs regulate gene expression? Sci STKE, 2007, re1.
36. Jenuwein T, Alllis CD: Translating the histone code. Science, 2001, 293, 1074-1079.
37. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov, 2002, 1, 287-299.
38. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell, 1980, 20, 85-93. (Pubitemid 10117303)
39. Jones SM, Boobis AR, Moore GE, Stanier PM: Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. Biochem Pharmacol, 1992, 43, 1876-1879.
40. Karlgren M, Gomez A, Stark K, Svard J, Rodriguez-Antona C, Oliw E, Bernal ML et al.: Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun, 2006, 341, 451-458.
41. Karlgren M, Miura S, Ingelman-Sundberg M: Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol, 2005, 207, 57-61.
42. Kastrup IB, Worm J, Ralfkiaer E, Hokland P, Guldberg P, Grønbaek K: Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol, 2008, 80, 81-66.
43. Kim DH, Rossi JJ: RNAi mechanisms and applications. Biotechniques, 2008, 44, 613-616. (Pubitemid 351656279)
44. Kouzarides T: Chromatin modofications and their function. Cell, 2007, 128, 693-705
45. Kristeleir R, Stimson L, Workman P, Aherene W: Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs, 2004, 9, 135-154. (Pubitemid 38715582)
46. Kucińska M, Piotrowska H, Murias M: Sirtuins - modulation of their activity as a novel therapeutic target (Polish). Pol Merkur Lekarski, 2010, 28, 231-235]
47. Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M, Wada M: Association of 5′-CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem, 1999, 262, 924-932. (Pubitemid 29291053)
48. Laird PW: Cancer epigenetics. Hum Mol Genet, 2005, 14, 65-76.
49. Laird P, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weiberg RA, Jaenisch R: Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 1995, 81, 197-205.
50. Lee WJ, Zhu RT: Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis, 2006, 27, 269-277. (Pubitemid 43159879)
51. Li Y, Cui Y, Hart SN, Klassen CD, Zhong XB: Dynamic patterns of histone methylation are associated with oncogenic expression of the CYP3A4 genes during mouse liver maturation. Mol Pharmacol, 2009, 75, 1171-1179.
52. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N: Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol, 2010, 79, 817-24.
53. Ling G, Wei Y, Ding X: Transcriptional regulation of human CYP2A13 expression in the respiratory tract by CCAAT/enhancer binding protein and epigenetic modulation. Mol Pharmacol, 2007, 71, 807-816. (Pubitemid 46294092)
54. Liu B, Lin Y, Darwanto A, Song X, Xu G, Zhang K: Identification and characterisation of propionylation at histone H3 lysine 23 in mammalian cells. J Biol Chem, 2009, 284, 32288-32295.
55. Luo W, Karf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL: Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res, 2010, 70, 5953-5962.
56. Marks PA, Richan VM, Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst, 2000, 92, 1210-1216. (Pubitemid 30627729)
57. Mateo Leach I, van der Harst P, de Boer RA: Pharmacoepigenetics in heart failure. Curr Heart Fail Rep, 2010, 7, 83-90.
58. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S.: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem, 2008, 283, 29897-29903.
59. Movassagh M, Choy MK, Goddard M, Bennett MR, Down TA, Foo RS: Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One 2010, 5, e8564.
60. Neugebauer RC, Sippl W, Jung M: Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr Pharm Des, 2008, 14, 562-573.
61. Novakovic B, Sibson M, Ng HK, Manuelpillai U, Rakyan V, Down T, Beck S et al.: Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem, 2009, 284, 14838-14848.
62. Okino ST, Pookot D, Li LC, Zhao H, Urakami S, Shiina H, Igawa M, Dahiya R: Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer. Cancer Res, 2006, 66, 7420-7428. (Pubitemid 44289194)
63. Oneta CM, Lieber CS, Li J, Rüttimann S, Schmid B, Lattmann J, Rosman AS, Seitz HK: Dynamics of cytochrome P4502E1 activity in man: induction by ethanol, and disappearance during withdrawal phase. J Hepatol, 2002, 36, 47-52. (Pubitemid 34234015)
64. Onica T, Nichols K, Larin M, Ng L, Maslen A, Dvorak Z, Pascussi JM et al.: Dexamethasone-mediated upregulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 α to the proximal promoter. Mol Pharmacol, 2008, 73, 451-460.
65. Paluszczak J, Baer-Dubowska W: Epigenetic diagnostics of cancer- the application of DNA methylation markers. J Appl Genet, 2006, 47, 365-375. (Pubitemid 44893733)
66. Paluszczak J, Baer-Dubowska W: Epigenome and cancer: new possibilities of cancer prevention and therapy? (Polish). Postȩpy Biochem, 2005, 51, 244-250.
67. Paluszczak J, Krajka-Kuźniak V, Baer-Dubowska W: The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett, 2010, 192, 119-125.
68. Pandey DP, Picard D: miR-22 inhibits estrogen signalling induces proliferation and migration of breast cancer cells through CTGF. Mol Cell Biol, 2009, 29, 3783-3790.
69. Park JY, Helm JF, Zheng W, Ly QP, Hodul PJ, Centeno BA, Malafa MP: Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas, 2008, 36, 32-39.
70. Peedicayil J: Epigenetic therapy - a new development in pharmacology. Indian J Med Res, 2006, 123, 17-24.
71. Peedicayil J: Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics, 2008, 9, 1785-1786.
72. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M: Molecular genetics and epigenetics of cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet, 2010, 127, 1-17.
73. Rønneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM, Yakhini Z et al.: GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Res, 2008, 68, 5562-5571.
74. Schroeder M, Krebs MO, Bleich S, Frieling H: Epigenetics and depression: current challenges and new therapeutic options. Curr Opin Psychiatry, 2010, 23, 588-592.
75. Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P, Ralhan R: CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem, 2010, 43, 373-379.
76. Smith LT, Otterson GA, Plass C: Unraveling the epigenetic code of cancer for therapy. Trends Genet, 2007, 23, 449-456. (Pubitemid 47259577)
77. Szyf M: Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics, 2004, 2, 357-377.
78. Takagi S, Nakajima M, Takagi S, Taniya T, Yokoi T: Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem, 2008, 283, 9674-9680.
79. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T et al.: Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res, 2005, 11, 5793-5801. (Pubitemid 41170305)
80. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T: MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res, 2006, 66, 9090-9098. (Pubitemid 44521128)
81. Urdinguio RG, Sanchez-Mut JV, Esteller M: Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol, 2009, 8, 1056-1072.
82. Valinluck V, Sowers LC: Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res, 2007, 67, 5583-5586. (Pubitemid 46984986)
83. Wang L, Oberg AL, Asmann YW, Sicotte H, McDonnell SK, Riska SM, Liu W: Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. PLoS One, 2009, 4, e5878.
84. Worm J, Kirkin AF, Dzhandzhugayan KN, Guldberg P: Methylation-dependent silencing of the reduced folate in inherently methotrexate-resistant human breast cancer cells. J Biol Chem, 2001, 276, 39990-40000.
85. Yang M, Li Y, Padgett RW: MicroRNAs: Small regulators with a big impact. Cytokine Growth Factor Rev, 2005, 16, 387-393. (Pubitemid 41024944)
86. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE: Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition, Cancer Res, 2000, 60, 6890-6894.
87. 2 gene in head and neck carcinogenesis. Clin Cancer Res, 2004, 10, 1733-1742.
88. Zeng Y: Principles of micro-RNA production and maturation. Oncogene, 2006, 25, 6156-6162.
89. Zhang B, Farwell MA: MicroRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med, 2008, 12, 3-21.